In this document I will aim to cover the following issues pertaining to the Case history given above. 1. What is the mechanistic difference between allergic and non-allergic urticaria. 2. I will detail my approach to investigating the underlying cause of the daily urticaria and intermittent angioedema in this patient given the limited information. 3. I will provide a short discussion on why I have chosen to use an experimental treatment agent. 4. I will characterise the effectiveness of this agent and evidence to obtain continued funding of the treatment.
Mechanistic difference between allergic and non-allergic urticaria.
Urticaria is a dermal oedema resulting from vascular dilation and leakage of fluid into the skin in response to mediators released from skin mast cells namely histamine and proteases. The activation of mast cells is a complex process that can be initiated by various signals often through specific mast cell surface receptors (1).
The mechanisms by which mast cells are activated and induce chronic urticaria is not fully understood, however they can separated into immunological and non-immunological (2).
IgE mediated allergic urticaria is , also known as a Type 1 hypersensitivity and is initiated by antigen/allergen binding to mast cell surface bound IgE leading to cross linking on the surface of mast cells and basophilis thus causing degranulation with histamine release (3).
Non allergic urticaria can be mediated by an auto immune response. Essentially auto-immune responses result from the binding of IgG autoantibodies to IgE and or to the IgE Fc receptors themselves on Mast Cells. These auto immune urticarias account for up to 50% of patients
References: 3. Linscott MS. Urticaria. http://emedicine.medscape.com.article/762917-overview (accessed 21 February 2013). 4.Powell et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clinical and Experimental Allergy 2007; 37(): 631-650. doi; 10.111/j.1365-2222.2007.02678.x (accessed 4 March 2013). 7. Maurer M, Ortonne T, Zuberbier T. Chronic Urticaria: a patient survey on quality-of-life, treatment usage and doctor-aptient relation. Allergy 2009; 64: 581-588. DOI:10.1111/J.1398-9995.2008.01853.X (accessed 1 March 2013). 8.Bennett R, Nelson D. Cognitive Behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006 Aug; 2 (8):416-24 9 10. BMJ. Medicines Complete- side effects of corticosteriods. http://www.medicinescomplete.com/mc/bnf/current/PHP4353-side-effects-of-corticosteroids.htm (accessed 11 March 2013). 12. Kapp A. Demarteau N. Cost Effectiveness of Levocetirizine in Chronic Idiopathic Urticaria. Clinical Drug Investigations 2006; 26(1): 1-11. http://www.medscape.com/viewarticle/521307 (accessed 8 March 2013). 13. Khan DA. Chronic Urticaria: Standard management and patient education. www.uptodare.com/contents/chronic-urticaria-standard-management_and_patient_education (accessed 7 March 2013).